0000950172-26-000183.txt : 20260715
0000950172-26-000183.hdr.sgml : 20260715
20260715164233
ACCESSION NUMBER: 0000950172-26-000183
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06c
FILED AS OF DATE: 20260715
DATE AS OF CHANGE: 20260715
EFFECTIVENESS DATE: 20260715
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cambrian BioPharma Inc
CENTRAL INDEX KEY: 0001797409
ORGANIZATION NAME:
EIN: 842985609
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-590950
FILM NUMBER: 261177828
BUSINESS ADDRESS:
STREET 1: 228 PARK AVENUE S.
STREET 2: #66643
CITY: NEW YORK
STATE: NY
ZIP: 10003
BUSINESS PHONE: (516) 962-3186
MAIL ADDRESS:
STREET 1: 228 PARK AVENUE S.
STREET 2: #66643
CITY: NEW YORK
STATE: NY
ZIP: 10003
FORMER COMPANY:
FORMER CONFORMED NAME: Cambrian BioPharma Inc.
DATE OF NAME CHANGE: 20191219
D
1
primary_doc.xml
X0708
D
LIVE
0001797409
Cambrian BioPharma Inc
228 Park Avenue South
Suite 66643
NEW YORK
NY
NEW YORK
10003
(516) 962-3186
DELAWARE
Cambrian BioPharma Inc.
Corporation
true
James
Peyer
228 Park Avenue South
Suite 66643
New York
NY
NEW YORK
10003
Executive Officer
Director
Juliette
Han
228 Park Avenue South
Suite 66643
New York
NY
NEW YORK
10003
Executive Officer
Director
Mark
Nuttall
228 Park Avenue South
Suite 66643
New York
NY
NEW YORK
10003
Executive Officer
Ruth
Thieroff-Ekerdt
228 Park Avenue South
Suite 66643
New York
NY
NEW YORK
10003
Executive Officer
William
DeVaul
228 Park Avenue South
Suite 66643
New York
NY
NEW YORK
10003
Executive Officer
Christian
Angermeyer
Centris Business Gateway, Level 0-C
Triq Is-Salib tal-Imriehel, Zone 3, CBD
Birkirkara
O1
MALTA
CBD 3020
Director
Maryanna
Saenko
465 First Street
Los Altos
CA
CALIFORNIA
94022
Director
Brenton
L.
Saunders
400 Somerset Corporate Boulevard
Bridgewater
NJ
NEW JERSEY
08807
Director
Paul
Farr
201 Santa Monica Boulevard
Santa Monica
CA
CALIFORNIA
90401
Director
Martin
Gunhaga
Vastra Kyrkogatan 1 A
Umea
V7
SWEDEN
SE-903 29
Director
Lorin
Van Nuland
Centris Business Gateway, Level 0/C
Triq Is-Salib tal-Imriehel, Zone 3, CBD
Birkirkara
O1
MALTA
CBD 3020
Director
Biotechnology
Decline to Disclose
- 06c
false
2026-06-30
false
true
true
46,210,122 shares were offered in a business combination whereby the Issuer issued 7,988,207 Common and 38,221,915 Preferred shares to shareholders of a certain company in exchange for their shares, increasing the Issuer's ownership to 100%.
0
129751064
123751064
6000000
false
80
0
0
0
false
Cambrian BioPharma Inc
/s/ William DeVaul
William DeVaul
Chief Legal Officer
2026-07-15